Summary
41X Chart
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story
Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript
Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ardelyx Inc. (41X) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ardelyx Inc. ever had a stock split?
Ardelyx Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael G. Raab CEO | XMUN Exchange | US0396971071 ISIN |
| US Country | 489 Employees | - Last Dividend | - Last Split | 19 Jun 2014 IPO Date |
Overview
Ardelyx, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines targeting gastrointestinal and cardiorenal therapeutic areas. The company's efforts are primarily focused on addressing the needs of patients in the United States and internationally. Ardelyx was originally established as Nteryx, Inc. and underwent a name change to Ardelyx, Inc. in June 2008. With its foundation in 2007 and headquarters situated in Waltham, Massachusetts, Ardelyx is at the forefront of developing potential treatments for various conditions related to the gastrointestinal tract and renal-cardiac health.
Products and Services
Ardelyx, Inc. is engaged in the development of a range of therapeutic products, including:
- Tenapanor: This is the lead product candidate of Ardelyx, aiming at treating patients suffering from irritable bowel syndrome with constipation (IBS-C). Tenapanor shows promise in alleviating symptoms associated with IBS-C, demonstrating Ardelyx's focus on addressing gastrointestinal disorders.
- XPHOZAH (Phase III): Currently in Phase III clinical trial, XPHOZAH is developed to reduce serum phosphorus in adults suffering from chronic kidney disease (CKD) on dialysis, or those with hyperphosphatemia. This treatment is indicative of Ardelyx's dedication to advancing care in the cardiorenal therapeutic area.
- RDX013: This potassium secretagogue is designed for the treatment of elevated serum potassium, or hyperkalemia, a frequent complication among patients with kidney and/or heart failure. RDX013 embodies the company's efforts to tackle key issues in cardiorenal health through innovative therapeutic solutions.
- RDX020: Targeted towards adult patients with metabolic acidosis, a serious electrolyte disorder, RDX020 is another testament to Ardelyx's commitment to addressing complex cardiorenal conditions.
In addition to developing these pioneering treatments, Ardelyx has forged strategic agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. These partnerships are focused on the development and commercialization of tenapanor in their respective territories, further illustrating Ardelyx's efforts to bring its innovative solutions to a global market.
